shutterstock_1904219086_ralf_liebhold
Ralf Liebhold / Shutterstock.com
5 July 2022

Fed Circuit to address cannabis clash

The dispute centres on a process for extracting CBD from cannabis plant material, which anticipates the use of CBD as an anti-epileptic treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 December 2020   Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.

More on this story

Americas
24 December 2020   Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.

More on this story

Americas
24 December 2020   Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.